Company: ABBV
Filing Date: 2025-02-14
Form Type: 10-K
Source: 0001551152-25-000020
Chunk: 367

Company: AbbVie Inc.
Filing Date: 2025-02-14
Form: 10-K
Item: Item 8
Chunk 367
---
 $436 $666 Other Eye CareUnited States$472 $433 $399 International375 370 348 Total$847 $803 $747 Other Key ProductsMavyretUnited States$595 $659 $755 International716 771 786 Total$1,311 $1,430 $1,541 CreonUnited States$1,383 $1,268 $1,278 Linzess/ConstellaUnited States$916 $1,073 $1,003 International38 35 32 Total$954 $1,108 $1,035 All other$3,032 $3,035 $4,137 Total net revenues$56,334 $54,318 $58,054 (a)Net revenues include ImmunoGen product revenues after the acquisition closing date of February 12, 2024.

99     |  2024 Form 10-K

Net revenues to external customers by geographic area, based on product shipment destination, were as follows:years ended December 31 (in millions)202420232022United States$43,029 $41,883 $45,713 Germany1,465 1,266 1,340 Japan1,122 1,008 956 Canada1,088 1,076 1,159 China917 950 912 France776 780 787 Spain528 501 506 United Kingdom522 417 462 Italy511 484 444 Brazil464 439 430 Australia463 472 508 All other countries5,449 5,042 4,837 Total net revenues$56,334 $54,318 $58,054 See the following for additional information about certain income and expenses included in net earnings: intangible assets amortization expense (Note 7), intangible assets impairment expense (Note 7), change in fair value of contingent consideration (Note 11), interest income and expense (Note 3), depreciation expense (Note 2), litigation matters (Note 15), income tax expense (Note 14) and restructuring expense (Note 8). Long-lived assets, primarily net property and equipment, by geographic area were as follows:as of December 31 (in millions)20242023United States $3,331 $3,139 Europe1,485